Following 3 days of incubation with atorvastatin (10(-4), 10(-5)

Following 3 days of incubation with atorvastatin (10(-4), 10(-5) and 10(-6) M), transcription levels of profibrotic cytokines (transforming growth factor-beta 1, connective tissue growth factor and TIMP1)

and procollagen la were analyzed by real time PCR. Proliferation was investigated by 5′-bromo-2′-deoxyuridine assays. alpha-Smooth muscle actin protein expression was examined by western blotting. Fluorescence-activated cell sorting analysis of Annexin V and propidium iodide were used to measure apoptosis. Furthermore, p21 western blotting and beta-galactosidase staining were investigated in MFB as senescence markers. Subsequently, hepatic expression of desmin and senescence markers were analyzed in the livers of rats receiving atorvastatin (15 mg/kg*d) for 1 week starting 3 and 5 weeks after BDL. Atorvastatin inhibited the activation of HSC to MFB and decreased cytokine and collagen production Z-VAD-FMK solubility dmso in MFB in vitro. In addition, proliferation, cytokine and collagen production of MFB were reduced by atorvastatin. Atorvastatin

initiated apoptosis at 10(-4) M and attenuated it at 10(-5) M. Atorvastatin induced p21 protein expression and beta-galactosidase staining of MFB in vitro and in vivo. Atorvastatin elicits similiar effects on MFB as previously seen in vivo: it decreases MFB turnover and fibrogenesis. We suggest that a further mechanism explaining these effects is senescence of cells. Laboratory Investigation (2012) 92, 1440-1450; doi:10.1038/labinvest.2012.106; published online 13 August 2012″
“Folate-dependent tRNA m(5)U methyltransferase TrmFO is a flavoprotein that catalyzes the C-5-methylation of uridine at position Metabolism inhibitor 54 in the T Psi C loop of tRNA in several bacteria. Here we report the cloning and optimization of expression in Escherichia colt BL21 (DE3) of untagged, N-terminus, C-terminus (His)(6)-tagged TrmFO from Bacillus subtilis. Tagged and untagged TrmFO were purified to homogeneity by metal affinity or ion exchange and heparin affinity, respectively, followed by size-exclusion chromatography.

The tag did not significantly alter the expression level, flavin content, activity and secondary structure of the protein. (C) 2010 Elsevier Inc. All rights reserved.”
“Although androgen resistance has been characterized in men with a normal chromosome complement and mutations in the androgen-receptor gene, a mutation in the gene encoding estrogen receptor a (ESR1) was previously described only in one man and not, to our knowledge, in a woman. We now describe an 18-year-old woman without breast development and with markedly elevated serum levels of estrogens and bilateral multicystic ovaries. She was found to have a homozygous loss-of-function ESR1 mutation in a completely conserved residue that interferes with estrogen signaling. Her clinical presentation was similar to that in the mouse orthologue knockout. This case shows that disruption of ESR1 causes profound estrogen resistance in women.

Comments are closed.